Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Podcast: MDMA CEO Mark Leahey On Industry's Hot Topics

Executive Summary

In an exclusive interview with Medtech Insight, MDMA's Mark Leahey – one of industry's top lobbyists – talked about the group's priorities over the past year and its continued work on hot-button issues, including medical device-tax repeal, reimbursement and implementing MDUFA IV provisions. He also discussed the imminent departure of US FDA Commissioner Scott Gottlieb and the recent federal government shutdown.

You may also be interested in...

Medtech Industry Groups Spend Millions In 2019 Lobbying For Device-Tax Repeal – And Much More

Industry trade groups spend millions of dollars and walk thousands of steps in the halls of the US Congress each year to persuade legislators and their staff to support votes on device-tax repeal, Medicare payment reform, and other issues. Using lobbying reports downloaded by a public interest group, Medtech Insight has analyzed what industry spent and paid out to hire legislative experts to lobby Congress in the first half of 2019, and which topics they lobbied for the most.

MDMA Praises Reintroduction Of STRONGER Patents Act In Senate

The Medical Device Manufacturers Association (MDMA) on 10 July praised US Senate reintroduction of the STRONGER Patents Act, designed to strengthen the US patents systems by making it easier and less costly for patent-holders to enforce their patents, including those which are the intellectual property of device-makers.  Mirror legislation was simultaneously proposed in the US House.

US FDA Adds 14 New Regulatory Tools To Help It Review Medical Devices

The tools include new laboratory methods, and computational models and simulations give the agency more capabilities to test and validate data in premarket submissions.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts